Involvement of adenosine A1 and A2A receptors on guanosine-mediated anti-tremor effects in reserpinized mice

Purinergic Signal. 2020 Sep;16(3):379-387. doi: 10.1007/s11302-020-09716-z. Epub 2020 Jul 28.

Abstract

Parkinson's disease (PD) signs and symptoms regularly include tremor. Interestingly, the nucleoside guanosine (GUO) has already proven to be effective in reducing reserpine-induced tremulous jaw movements (TJMs) in rodent models, thus becoming a promising antiparkinsonian drug. Here, we aimed at revealing the mechanism behind GUO antiparkinsonian efficacy by assessing the role of adenosine A1 and A2A receptors (A1R and A2AR) on GUO-mediated anti-tremor effects in the reserpinized mouse model of PD. Reserpinized mice showed elevated reactive oxygen species (ROS) production and cellular membrane damage in striatal slices assessed ex vivo and GUO treatment reversed ROS production. Interestingly, while the simultaneous administration of sub-effective doses of GUO (5 mg/kg) and SCH58261 (0.01 mg/kg), an A2AR antagonist, precluded reserpine-induced TJMs, these were ineffective on reverting ROS production in ex vivo experiments. Importantly, GUO was able to reduce TJM and ROS production in reserpinized mouse lacking the A2AR, thus suggesting an A2AR-independent mechanism of GUO-mediated effects. Conversely, the administration of DPCPX (0.75 mg/kg), an A1R antagonist, completely abolished both GUO-mediated anti-tremor effects and blockade of ROS production. Overall, these results indicated that GUO anti-tremor and antioxidant effects in reserpinized mice were A1R dependent but A2AR independent, thus suggesting a differential participation of adenosine receptors in GUO-mediated effects.

Keywords: Adenosine receptors; Guanosine; Reserpine; Tremor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine A1 Receptor Antagonists / pharmacology
  • Adenosine A2 Receptor Antagonists
  • Animals
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / metabolism
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Guanosine / pharmacology
  • Guanosine / therapeutic use*
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Male
  • Mice
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / drug therapy
  • Parkinson Disease, Secondary / metabolism*
  • Reactive Oxygen Species / metabolism
  • Receptor, Adenosine A1 / metabolism*
  • Receptor, Adenosine A2A / metabolism*
  • Tremor / chemically induced
  • Tremor / drug therapy
  • Tremor / metabolism*
  • Xanthines / pharmacology

Substances

  • Adenosine A1 Receptor Antagonists
  • Adenosine A2 Receptor Antagonists
  • Reactive Oxygen Species
  • Receptor, Adenosine A1
  • Receptor, Adenosine A2A
  • Xanthines
  • Guanosine
  • 1,3-dipropyl-8-cyclopentylxanthine